South Korea-based bio-healthcare company Dx&Vx (DXVX) announced on Thursday the acceleration of its development programme for a universal COVID-19 vaccine, following the recent acquisition of related technology.
The company says that the vaccine is designed to provide immunity against both current and future variants of the coronavirus, amid a new wave of COVID-19 cases worldwide.
DXVX secured the universal vaccine technology late last year. The vaccine under development uses a virus-like particle (VLP) platform, which is claimed to offer greater stability and ease of storage compared to mRNA vaccines.
Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants.
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval
GSK grants USD2m to boost adult vaccination efforts
Valneva and LimmaTech begin Phase 2 infant trial for Shigella vaccine candidate S4V2
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention